Stay updated on Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial
Sign up to get notified when there's something new on the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page.

Latest updates to the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added to the history; the notices about funding and operating status and the prior Revision: v3.4.1 entry were removed. These are administrative updates that do not alter the core study content or data on the page.SummaryDifference0.8%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added and the page revision label updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check28 days agoChange DetectedGlossary visibility is added and change diffs are shown with color highlights (green for additions, red for deletions), and the revision label updated to v3.4.0.SummaryDifference1%

- Check64 days agoChange DetectedRevision: v3.3.3 was added to the record history, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' entries were removed from the footer/versions view; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check85 days agoChange DetectedRecord History now shows Revision: v3.3.2 in place of Revision: v3.3.1. This is a minor UI label change and does not affect study data or functionality.SummaryDifference0.1%

- Check92 days agoChange DetectedThe record history now includes an added Revision v3.3.1 entry and the v3.2.0 entry has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Encorafenib and Binimetinib in BRAF+ Stage II Melanoma Clinical Trial page.